Skip to main content
Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
14.37
+0.05 (0.35%)
At close: Mar 9, 2026, 4:00 PM EDT
14.38
+0.01 (0.07%)
After-hours: Mar 9, 2026, 5:41 PM EDT

Aurinia Pharmaceuticals Revenue

In the year 2025, Aurinia Pharmaceuticals had annual revenue of $283.06M with 20.38% growth. Aurinia Pharmaceuticals had revenue of $77.11M in the quarter ending December 31, 2025, with 28.81% growth.

Revenue (ttm)
$283.06M
Revenue Growth
+20.38%
P/S Ratio
6.66
Revenue / Employee
$2,211,367
Employees
128
Market Cap
1.91B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025283.06M47.92M20.38%
Dec 31, 2024235.13M59.62M33.97%
Dec 31, 2023175.51M41.48M30.95%
Dec 31, 2022134.03M88.43M193.89%
Dec 31, 202145.61M-4.51M-9.00%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Ultragenyx Pharmaceutical 673.00M
Stoke Therapeutics 205.63M
Soleno Therapeutics 190.41M
Syndax Pharmaceuticals 172.35M
Zymeworks 105.97M
Recursion Pharmaceuticals 74.68M
Nektar Therapeutics 62.60M
Celldex Therapeutics 1.55M
Revenue Rankings

AUPH News

More News